Pre-Eclampsia - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pre-Eclampsia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Pre-Eclampsia - Pipeline Review, H1 2016', provides an overview of the Pre-Eclampsia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
- The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects
- The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pre-Eclampsia Overview 6
Therapeutics Development 7
Pipeline Products for Pre-Eclampsia - Overview 7
Pre-Eclampsia - Therapeutics under Development by Companies 8
Pre-Eclampsia - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Pre-Eclampsia - Products under Development by Companies 12
Pre-Eclampsia - Companies Involved in Therapeutics Development 13
A1M Pharma AB 13
Alnylam Pharmaceuticals, Inc. 14
Glenveigh Medical, LLC 15
Pluristem Therapeutics Inc. 16
rEVO Biologics, Inc. 17
RTI International 18
VG Life Sciences, Inc. 19
Pre-Eclampsia - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
A1M-001 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ALN-AGT - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
antithrombin alfa (recombinant) - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
digoxin immune fab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PLX-PAD - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Agonize CLR and RAMP Receptors for Pre-Eclampsia - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VG-1177 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Pre-Eclampsia - Recent Pipeline Updates 44
Pre-Eclampsia - Dormant Projects 53
Pre-Eclampsia - Product Development Milestones 54
Featured News & Press Releases 54
Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Preeclampsia 54
Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells 54
Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Preeclampsia 56
Sep 24, 2015: New clinical trial at SLU treats preeclampsia in second-trimester pregnancies 56
Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia 57
Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 59
Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1) 59
Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Preeclampsia 60
Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia 60
Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables

Number of Products under Development for Pre-Eclampsia, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Pre-Eclampsia - Pipeline by A1M Pharma AB, H1 2016 13
Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 14
Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H1 2016 15
Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H1 2016 16
Pre-Eclampsia - Pipeline by rEVO Biologics, Inc., H1 2016 17
Pre-Eclampsia - Pipeline by RTI International, H1 2016 18
Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Pre-Eclampsia Therapeutics - Recent Pipeline Updates, H1 2016 44
Pre-Eclampsia - Dormant Projects, H1 2016 53